NCT07010705Recruiting
Digital Measures for Clinical Trial Endpoints in Huntington's Disease
Digital Measures for Clinical Trial Endpoints in Huntington's Disease (MEND-HD)
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life. The study may be extended to 3 years to include yearly visits.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 30 May 2025
- Start date
- 20 Jun 2025
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- University of Rochester
- Diseases
- Huntington's disease
- NCT number
- NCT07010705
What you commit to
- Study type: Observational
- Planned participants: 100
- From 20 Jun 2025 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe
- Acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic,
- cardiovascular or psychiatric disease.
Other
- Diagnosis of juvenile-onset HD.
- Traumatic Brain Injury.
- Use of an assistive device for ambulation.
- Montreal Cognitive Assessment (MoCA) score of 18 or lower
- Pregnancy
- Cannot be enrolled into a blinded intervention trial at Baseline
Who the study is looking for
- Age of 25-65 years.
- Genetically confirmed HD with CAG \>= 40 (HD-ISS Stage 2 or mild/moderate Stage 3)
- English speaking.
- Age of 25-65 years.
- English speaking.
- Self-identified support person or family member of the enrolled participants with HD.
- 18 years or older
- English speaking.
Age in the registry: 25 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Rochester Medical Center Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.